Artal Group S.A. Adverum Biotechnologies, Inc. Transaction History

Artal Group S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	BUY	$3.36 - $10.56 $2.02 Million - $6.34 Million	600,000 Added 25.0%	3,000,000 $10.5 Million
Q1 2021 May 14, 2021	SELL	$9.26 - $14.36 $926,000 - $1.44 Million	-100,000 Reduced 4.0%	2,400,000 $23.7 Million
Q4 2020 Feb 11, 2021	BUY	$9.84 - $14.26 $6.89 Million - $9.98 Million	700,000 Added 38.89%	2,500,000 $27.1 Million
Q3 2020 Nov 13, 2020	BUY	$10.3 - $21.64 $9.27 Million - $19.5 Million	900,000 Added 100.0%	1,800,000 $18.5 Million
Q2 2020 Aug 14, 2020	BUY	$8.53 - $25.64 $2.56 Million - $7.69 Million	300,000 Added 50.0%	900,000 $18.8 Million
Q1 2020 May 14, 2020	BUY	$7.98 - $16.32 $4.79 Million - $9.79 Million	600,000 New	600,000 $5.86 Million
Q4 2018 Feb 11, 2019	SELL	$2.87 - $5.92 $1.15 Million - $2.37 Million	-400,000 Closed	0 $0
Q1 2018 May 10, 2018	BUY	$3.65 - $7.95 $1.46 Million - $3.18 Million	400,000 New	400,000 $2.32 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.